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Abstract 
Oxadiazole ring system occupies a significant position among heterocyclic templates for medicinal 
compounds due to its wide spectrum of biological activities. This article entails an in-depth review of the 
ability of oxadiazole derivatives to induce apoptosis of cancer cells. FDA has approved a number of 
drugs for the treatment of different types of cancer.  There is, however, a continuing need for the 
development of new anticancer agents due to increasing cases of drug resistance. Moreover, medicinal 
chemists are continuously struggling to invent selective cytotoxic agents with minimum side effects. This 
work reviews the significance of oxadiazole ring system and its potential to act as a template for novel 
anticancer agents. 
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Cancer is a continued threat for humanity on the 
globe both in advanced countries as well as 
developing ones. Various anticancer drugs have 
been approved by FDA for the treatment of 
different types of cancers. Most of them are 
structurally based upon heterocyclic ring 
systems. Oxadiazole ring system is at significant 
position among heterocycles due its medicinal 
properties. This ring system exists in the form of 
structural isomers 1,3,4-oxadiazole, 1,2,4- 




1,3,4-Oxadiazole derivatives are frequently 
reported for their anticancer activity. A series of 
1-[{(5-Alkenyl/hydroxyalkenylsubstituted)-1,3,4-
oxadiazol-2-yl}-methyl]-2-methyl-1H-
benzimidazoles has been recently reported as 
anticancer agents. Among them, compounds 1, 2 
& 3 showed moderate to weak activity against 
Hep3B (human hepatocellular carcinoma), HeLa 
(human cervical carcinoma) and MCF 7 (human 
breast adenocarcinoma) cell lines (Table 1) [1].  
A series of indole and 1,3,4-oxadiazole hybrid 
compounds were recently prepared by Hatti and 
coworkers and were screened against MCF-7, 
KB, Colo-205, and A-549 cancer cell lines. 
Among them, compounds 4-8 were found to 
exhibit significantly higher anticancer activity as 
compared to the reference drug etoposide (Table 
2) [2]. Rashid et al prepared 3-((5-(3-(1H-
benzo[d]imidazol-2-yl)-3-oxopropyl)-1,3,4-oxadia-
zol-2-yl)methyl)-5-methylpyrimidine-2,4(1H,3H)-
dione (9) which exhibited significant 
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antiproliferative activity with GI50 value of 0.09 
µM [3].  
 
Yonova et al reported 2-phenyl-5-(phenylthio)-
1,3,4-oxadiazole (10) as selective anticancer 
agent against the MCF-7 with EC50 value of 7.9 
µM [4]. Valente et al described the synthesis of 
hydroxamates and 2-aminoanilides having 1,3,4-
oxadiazole moiety as histone deacetylase 
inhibitors. Among the series of naphthalene 
based oxadazoles, compounds 11 and 12 
appeared as the most potent and selective 
compounds against HDAC1. Compound 11 was 
more effective against U937 leukemia cells with 
IC50 value of 7.8 μM than reference drug (SAHA) 
and compound 12 displayed cell di erentiation 
comparable to reference, MS-275 [5]. Kumar et 
al synthesized oxadiazole containing 
sulfonamides 13 and 14 which were weakly 
active against K562, Colo-205, MDA-MB231 and 




         Figure 1: Structures of 1,3,4-Oxadiazoles (1-12) exhibiting potent anticancer activity 
 
Table 1: IC50 (µM) values of compounds 1 - 3 against various cancer cell lines 
 
Compound Hep3 B MCF 7  HeLa  PBMC 
1 11.10 ± 1.1 12.40 ± 0.5 11.70 ± 2.9 42.42 ± 1.2 
2 14.10 ± 0.8 12.20 ± 0.7 14.40 ± 1.2 41.27 ± 1.8 
3 13.90 ± 0.8 11.10 ± 0.7 10.60 ± 1.2 43.28 ± 1.8 
Doxo 02.35 ± 1.2 03.12 ± 1.7 03.56 ± 2.7 09.23 ± 2.6 
5-Fu 03.45 ± 2.1 04.12 ± 2.3 02.78 ± 2.6 08.91 ± 1.9 
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Table 2: Cytotoxic activity (GI50/µM) of compounds 4 – 8 
 
Compound Breast MCF-7 Oral KB Colon Colo-205 Lung A-549 
4 <0.1  <0.1  1.3  <0.1 
5 0.12 –  0.13 <0.1 
6 0.14  <0.1  <0.1  <0.1 
7 <0.1  0.11  –  <0.1 
8 <0.1  0.18  0.15  <0.1 
Etoposide  2.11  0.31  0.13  3.08 
 
Table 3: Anti-proliferative activity (% cell survival) of compounds 13 and 14 (10 µM) 
 
Compound K562  Colo-205  MDA-MB 231  IMR-32 
13 59.31  64.00  62.40  68.22 
14 48.20  61.70  60.05  60.81 
Control (0.1 % DMSO) 100 100 100 100 
 
Zhang et al reported the synthesis of structural 
hybrids of 1,3,4-oxadiazole and 1,3,4-thiadiazole 
heterocycles having schiff base side chain. 
Among these compounds, compound 15 
exhibited growth inhibition of SMMC-7721 cells 
with IC50 value of 2.84 µM. Compounds 16 and 
17 displayed antitumor activity with IC50 values of 
4.56 and 4.25 µM, respectively against MCF-7 
cells. Compounds 17 and 18 exhibited significant 
anti-proliferative activity against A549 cells, with 
IC50 values of 4.13 and 4.11 µM, respectively [7]. 
Quinoline substituted 1,3,4-oxadiazoles are 
reported for their inhibitory potential against 
HepG2, SGC-7901 and MCF-7 cell lines. Among 
the series, compounds 19 and 20 showed the 
best activity among the series and the results 
were comparable to the control as shown in table 
4 [8]. Murty et al coupled piperazine substituted 
benzothiazole/benzoxazole with 1,3,4-
oxadiazole-2-thiol to get corresponding structural 
hybrids 21 and 22 which displayed excellent 
cytotoxic activity as shown in the Table 5 [9]. 
 
 
Figure 2: Structures of 1,3,4-Oxadiazoles (13-22) exhibiting potent anticancer activity 
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1,3,4-Oxadiazoles derivatives (23  and 24) 
exhibited good activity with IC50 values of 16 µM 
and 10 µM respectively against K562 cancer cell 
line [10]. Shamsuzzaman et al synthesized 25 
that exhibited moderate anticancer behavior 
against human leukemia cell line (HL-60) (IC50 
=17.33) [11]. 
 
Bondock et al synthesized heterocyclic 1,3,4-
oxadiazole derivatives derivatives (25-30) that 
displayed promising in-vitro antitumor activity as 
shown in the Table 6 [12]. Feng et al synthesized 
a series of thio-substituted 1,3,4-oxadiazole 
derivatives (31 & 32) and screened them against 
human leukemia tumor cell line (K-562). 
Compounds 31 and 32 were docked into the 
ATPase domain of TP-II and docking scores are 
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   Figure 3: Structures of 1,3,4-Oxadiazoles (23-38) exhibiting potent anticancer activity 
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Table 4: Anticancer activities (IC50, µM) of compounds 19 and 20  
 
Compound  HepG2 SGC-7901 MCF-7 
19 1.2±0.2 8.3±1.6 6.8±0.5 
20 0.8±0.2 7.6±1.0 7.1±0.8 
 
Table 5:  Cytotoxic activity (IC50, µM) of compounds 21 and 22 
 
Compound MCF 7  HeLa  A431  HepG2 A549 
21 52.7  63.9  36.9  88.9  102.0 
22 39.0  78.1  55.9  325.1  88.7 
Curcumin 26.0  17.0 22.0  16.0  22.0 
 
Table 6:  Cytotoxicity values [IC50 (µg/ml)] of compounds 26 – 30 
 
Compound HepG2  WI-38  VERO  MCF-7 
26 21.2 24.4  30.3 39.2 
27 12.4 17.3  15.8  25.8 
28 33.7  38.4  36.3  38.3 
29 38.1  24.1 39.6  37.4 
30 35.6  35.8  34.5  32.6 
5-Fu 8.6  3.2  6.5  2.3 
 
Table 7: Docking score and IC50 values for compounds 31 and 32 
 
Compound Glide {TP-II (PDB: 
1ZXM)} 
Glide {Tubulin (PDB: 
1SA0)} 
K562 [IC50 (µM)] 
31 >-5 >-5 31.14 
32 -6.87 >-5 43.55 
Hydroxy-urea (standard 
drug) 
- - 687.94 
 
Benzimidazole and oxadiazole hybrids were synthesized by Rashid et al. Amongst them, compound 
33 emerged as the most significant anticancer agent against various cancer cell lines [14]. Husain et 
al also synthesized benzimidazole and oxadiazole hybrids. Among them, compound 34 exhibited 
significant growth inhibition  [15]. Fadda et al synthesized a new series of quinoline based 
oxadiazoles. The compound 35 showed a strong cytotoxicity as shown in the Table 8 [16]. 
 
Gudipati et al synthesized a series of indole containing oxadiazoles. The compounds produced a dose 
dependent inhibition of the growth of HeLa cancer cell line. The IC50 values were found between 
10.64 and 33.62 µM. The compounds 36, 37 & 38 exhibited anticancer activity comparable to 
Cisplatin (Table 9) [17]. 
 
Dash et al synthesized the series of 3,5-disubstituted 1,3,4-oxa-diazole-2-thione derivatives. Among 
the synthesized compounds, the compounds 39, 40, 41, 42 & 43 were found more active than 5-FU 
as shown in Table 10 [18]. Zhang et al synthesized 1,4-benzodioxane based 1,3,4-oxadiazoles as 
potential telomerase inhibitors. Compounds 44, 45, 46, 47 and 48 were observed as potent anticancer 
compounds with IC50 concentration range from 7.21 µM to 25.87 µM against HEPG2, SW1116, HELA 
and BGC823 [19]. 
 
Abu-Zaied et al synthesized novel thioglycosides having 1,3,4-oxadiazole moiety. The 
pharmacological evaluation of compounds 49, 50 and 51 was carried out and the compounds were 
found to be effective against MCF-7 (breast) and HEPG2 (liver) cells. The IC50 values were found in 
the range of 2.67-20.25 (µg/mL) for MCF-7 (breast cancer cell line) and 4.62-43.6 (µg/mL) for HEPG2 
(liver cancer cell line) [20]. 
 
5-(3-Indolyl)-2-(substituted)-1,3,4-oxadiazoles were screened for human cancer cell lines and among 
the compounds, compounds 52, 53 and 54 exhibited potent cytotoxicity (IC50~1 µM) and selectivity 
against human cancer cell lines as shown in Table 11 [21]. Tong et al. described the synthesis of 
compound 55 showed the best activity with EC50 value of 3.7 µM [22]. Oxadiazole compounds 56 and 
57 were appeared as potent members of anticancer family of drugs [23]. 
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There are sufficient number of evidence dealing 
with anticancer behavious of 1,2,4-oxadiazole 
derivatives. 5-(5,7-Dimethylpyrazolo[1,5-
a]pyrimidin-3-yl)-3-(piperazin-1-ylmethyl)-1,2,4-
oxadiazole based carboxamides, sulfonamides, 
ureas, and thioureas are recently reported for  
 
 
       Figure 4: Structures of anticancer 1,3,4-Oxadiazoles (39-57) 
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Table 8: Cytotoxicity of the Synthesized Compound 35 (IC50, μg/ml) 
 
Compound HepG2   WI-38   VERO   MCF-7 
35 22.4    27.3    25.8    40.8 
5-Fluorouracil    8.6    3.2    6.5   2.3 
       Table 9: Cytotoxicity of the Synthesized Compounds 36-38 (IC50, μg/ml) 
 
Compound IC50 (µM, HeLa)  IC50 (µM, IMR-32)  IC50 (µM, MCF-7) 
36 11.99  13.48  15.57 
37 12.84  15.84  16.68 
38 10.64 12.68 16.06 
Cisplatin  14.08  13.64  13.54 
 
   Table 10: Anticancer activity of oxadiazole derivatives against EAC bearing mice 
 
Compound RBC (106 cells) WBC (103 cells) 
Normal saline  11.04 ± 0.33  4.47 ± 0.15 
Induce control  2.77 ± 0.13  10.31 ± 0.23 
39 3.57 ± 0.20*  7.73 ± 0.21*** 
40 5.68 ± 0.30*** 5.57 ± 0.14*** 
41 7.23 ± 0.07*** 4.47 ± 0.12*** 
42  6.25 ± 0.16*** 4.97 ± 0.10*** 
43  8.27 ± 0.16*** 4.62 ± 0.14*** 
5-Fluorouracil 8.32 ± 0.15*** 4.81 ± 0.14*** 
      Test compounds were compared with induce control; * p < 0.05, *** p < 0.01 
 
   Table 11: Cytotoxicity (IC50, µM) of 5-(3-indolyl)-2-(substituted)-1,3,4-oxadiazoles (52 - 54) 
 
Compound PC3 DU145 LnCaP MDA-MB-231  MCF7 PaCa2 
52 4.1 20.4 10.0 >103 1.0 1.6 
53 710.8 170 69.4 >103 5.4 0.9 
54 >103 >103 >103 >103 35.2 1.4 
 
their effective activity against HeLa cells. Five 
compounds 58-62 exhibited activity with IC50 
value <10 µg/cm3 which was greater than 
reference drug, paclitaxel with IC50 value 30 
µg/cm3 [24]. Miralinaghi et al described the 
synthesis of triaryl-1,2,4-oxadiazole derivatives 
and screened them for anti-proliferative activities 
against MCF7 and K562 cell lines using MTT 
assay. Out of these, compound 63 showed 
remarkable activity against MCF7 and K562 cell 
lines with IC50 values of 6.50 and 21.66 µM, 
respectively [25]. 
 
Tsygankova and Zhenodarova reported a series 
of 3,5-Diaryl-1,2,4-oxadiazoles derivatives. Five 
compounds (64-68) were found more active 
against antitumor agents as shown in the table 
12 [26]. 1,2,4-Oxadiazole (69) exhibited effective 
activity against DU145 (IC50 : 9.3 µM) cell lines 
[27]. 
 
Previously, Yang et al synthesized the series of 
Oxadiazole derivatives as inhibitors of human 
leukemia HL-60 cells. Compound 70 was one of 
the potent anti-proliferative agent without 
inhibition of GST P1-1 activity. Compounds 71 
and 72 exhibited antitumor activity with IC50 value 
less than 5 μM as shown in the table 13 [28]. 
Kemnitzer et al synthesized a new series of 3-
aryl-5-aryl-1,2,4-oxadiazoles. Compound 73 was 
found more active against T47D cancer cell 
growth with GI50 value of 0.13µM [29]. Kumar et 
al synthesized a series of 3,5-disubstituted-1,2,4-
oxadiazoles. Compound 74 appeared as the 
most selective (>450-fold) whereas 75 as the 
most potent compound having IC50 value of 10 
nM against prostate cancer cell lines (Table 14) 
[30]. 
 
Thiophene containing 1,2,4-oxadiazole (76) has 
been found as good anticancer compound 
against several breast and colorectal cancer cell 
lines as reported by Zhang et al. Moreover, 
compound 77 has been found to have in vivo 
activity in a MX-1 tumor model as shown in the 




In contrast to other oxadiazoles, 1,2,3-oxadiazole 
ring system is unstable. It isomerizes to 
formyldiazomethane [32, 33]. That's why, it is 
least studied for its biological activities. 
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    Figure 5: 1,2,4-Oxadiazoles (55-69) exhibiting potent anticancer activity 
 
 
Figure 6: 1,2,4-Oxadiazoles (70-77) exhibiting potent anticancer activity 
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Table 12: 3-Aryl-5-aryl-1,2,4-oxadiazoles (64-68) as 
anticancer agents 
 







Table 13: Growth inhibition of GST P1-1 and HL-60 
cells by compounds 70-72 
 




GI50 (μM) for 
inhibiting HL 
60 cell growth 
70 >40  1.1 ± 0.2 
71 4.0 ± 0.3  2.3 ± 0.2 
72 3.6 ± 0.7  1.7 ± 0.1 
 
Table 14: Cytotoxicity profile of 3,5-disubstituted-1,2,4-oxadiazoles (IC50 (µM) 
 
Compounds PC3 DU145 LnCaP MCF7 MDA231 HCT116 PaCa2 
74 >103 242±0.1 0.043±0.04 >103 212.2±0.3  184.8 ± 0.1  19.49 ± 0.08 
75 >103 0.057±0.07 0.010±0.02 3.88±0.3 0.37±0.08 1.54 ± 0.03 0.54 ± 0.03 
 
Table 15: Cell Growth Inhibition Activity of 3-Aryl-5-
aryl-1,2,4-oxadiazoles (GI50, µM) 
 
Compounds T47D  DLD1  H1299 
76 0.22 ± 0.05  0.77 ± 0.29 >10 




We have summed up recent literature dealing 
with anticancer behavior of oxadiazole ring 
system. Keeping in view the focus of article, we 
have mentioned only the potent anticancer 
compounds of the family. The data presented in 
this article is collected from recent publications in 
well reputed international journals of medicinal 
and pharmaceutical chemistry. The structural 
features could be interesting for medicinal 
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